Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)’s share price gapped up before the market opened on Tuesday . The stock had previously closed at $122.31, but opened at $122.31. Alnylam Pharmaceuticals shares last traded at $122.04, with a volume of 542,654 shares.

A number of equities analysts have recently issued reports on ALNY shares. Needham & Company LLC restated a “buy” rating and set a $85.00 target price (down from $98.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday, September 7th. Zacks Investment Research upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating and set a $88.00 target price on the stock in a research report on Wednesday, July 12th. BMO Capital Markets restated an “outperform” rating and set a $99.00 target price (down from $105.00) on shares of Alnylam Pharmaceuticals in a research report on Wednesday, September 6th. Piper Jaffray Companies restated an “overweight” rating and set a $110.00 target price (down from $126.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday, September 7th. Finally, Instinet started coverage on shares of Alnylam Pharmaceuticals in a research report on Friday, September 15th. They set a “reduce” rating and a $56.00 target price on the stock. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and fifteen have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $98.63.

The firm’s market capitalization is $11.02 billion. The company’s 50 day moving average is $92.39 and its 200-day moving average is $74.09.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.22) by ($0.12). Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. The firm had revenue of $15.93 million for the quarter, compared to analysts’ expectations of $23.86 million. During the same period last year, the business earned ($1.05) earnings per share. The firm’s revenue for the quarter was up 82.9% on a year-over-year basis. On average, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post ($5.20) earnings per share for the current fiscal year.

In other news, President Barry E. Greene sold 85,316 shares of the stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $125.00, for a total transaction of $10,664,500.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, President Barry E. Greene sold 76,815 shares of the stock in a transaction dated Wednesday, September 20th. The shares were sold at an average price of $100.00, for a total value of $7,681,500.00. Following the transaction, the president now directly owns 165,399 shares in the company, valued at approximately $16,539,900. The disclosure for this sale can be found here. 4.30% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the company. PNC Financial Services Group Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 0.4% during the 1st quarter. PNC Financial Services Group Inc. now owns 8,685 shares of the biopharmaceutical company’s stock valued at $446,000 after acquiring an additional 36 shares during the last quarter. State of Wisconsin Investment Board grew its holdings in Alnylam Pharmaceuticals by 0.7% in the 2nd quarter. State of Wisconsin Investment Board now owns 15,012 shares of the biopharmaceutical company’s stock valued at $1,197,000 after buying an additional 100 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in Alnylam Pharmaceuticals by 7.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 167 shares during the last quarter. Prudential Financial Inc. grew its holdings in Alnylam Pharmaceuticals by 4.8% in the 2nd quarter. Prudential Financial Inc. now owns 4,404 shares of the biopharmaceutical company’s stock valued at $351,000 after buying an additional 200 shares during the last quarter. Finally, Utah Retirement Systems grew its holdings in Alnylam Pharmaceuticals by 1.5% in the 2nd quarter. Utah Retirement Systems now owns 13,800 shares of the biopharmaceutical company’s stock valued at $1,100,000 after buying an additional 200 shares during the last quarter. 94.25% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/alnylam-pharmaceuticals-inc-alny-shares-gap-up-to-122-31/1609157.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.